Skip to main content
SpringerLink
Log in

Adipöser Patient mit Luftnot und Stauungsdermatitis

Obese patient with air hunger and stasis dermatitis

  • Bild und Fall
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Masani N, Jhaveri KD, Fishbane S (2014) Update on membranoproliferative GN. Clin J Am Soc Nephrol 9(3):600–608

    Article  PubMed  PubMed Central  Google Scholar 

  2. Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, Sinclair R, McNeil JJ, Atkins RC (2001) The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 16:1364–1367

    Article  CAS  PubMed  Google Scholar 

  3. Hohenstein B, Licht C, Wiesener M, Amann K, Schaefer F, Serka C, Bergmann C, Kirschfink M, Zipfel P, Hugo C (2015) „State-of-the-art“: C3-glomerulopathie und membranoproliferative glomerulonephritis. Nephrologe 10:327–340

    Article  Google Scholar 

  4. Rennke HG (1995) Secondary membanoproliferative glomerulonephritis. Kidney Int 47:643–656

    Article  CAS  PubMed  Google Scholar 

  5. Kuhlmann U, Böhler J, Luft FC, Kunzendorf U, Alscher MD (2015) Nephrologie: Pathophysiologie – Klinik – Nierenersatzverfahren, 6. Aufl. Thieme, Stuttgart, S 123–127

    Google Scholar 

  6. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int 2008; 73: 69–77.

  7. Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC (2010) Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 5:770–782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA, International Kidney and Monoclonal Gammopathy Research Group (2012) Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood 120:4292–4295

    Article  CAS  PubMed  Google Scholar 

  9. Bomback AS, Appel GB (2012) Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 8:634–642

    Article  CAS  PubMed  Google Scholar 

  10. Deltas C, Gale D (2013) Cook Tet al C3 glomerulonephritis/CFHR5nephropathy is an endemicdisease in Cyprus: Clinical and molecular findings in 21 families. Adv Exp Med Biol 735:189–196

    Article  CAS  PubMed  Google Scholar 

  11. Lesher AM, Zhou L, Kimura Y et al (2013) Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol 24:53–65

    Article  CAS  PubMed  Google Scholar 

  12. Leroy V, Fremeaux-Bacchi V, Peuchmaur M et al (2011) Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 26:419–424

    Article  PubMed  Google Scholar 

  13. Power DA, Ng YC, Simpson JG (1990) Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis. Q J Med 75:387–398

    CAS  PubMed  Google Scholar 

  14. Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis – A new look at an old entity. N Engl J Med 366:1119–1131

    Article  CAS  PubMed  Google Scholar 

  15. Pickering M, Cook HT (2011) Complement and glomerular disease: New insights. Curr Opin Nephrol Hypertens 20:271–277

    Article  CAS  PubMed  Google Scholar 

  16. Sethi S, Gamez JD, Vrana JA et al (2009) Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 75:952–960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Alchi B, Jayne D (2010) Membranoproliferative glomerulonephritis. Pediatr Nephrol 25(8):1409–1418

    Article  PubMed  Google Scholar 

  18. KDIGO-Leitlinien zur Behandlung von Glomerulonephritiden 2012.

  19. Gulard E, Karras A, Plalsler E et al (2011) Patterns of noncryoglobulinämic glomerulonephritis with monoklonal IgG depots. Korrelation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6:1609–1616

    Article  CAS  Google Scholar 

  20. Zäuner I, Böhler J, Braun N et al (1994) Effect of Aspirin and dypiridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: A multisentre clinical trial. Collaborative Glomerulonephritis Therapy Study Group. Nephrol Dial Transplant 9:619–622

    PubMed  Google Scholar 

  21. The Southwest Pediatric Nephrology Study Group (1985) Dense deposit disease in children: Prognostic value of clinical and pathologic indicators. Am J Kidney Dis 6(3):161–169

    Article  Google Scholar 

  22. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. (1992) Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone – a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 6:123–130

    Article  CAS  PubMed  Google Scholar 

  23. Kiyomasu T, Shibata M, Kurosu H et al (2002) Cyclosporin A treatment for membranoproliferative glomerulonephritis type II. Nephron 91:509–511

    Article  PubMed  Google Scholar 

  24. Banks RA, May S, Wallington T (1982) Acute renal failure in dense deposit disease: Recovery after plasmapheresis. Br Med J (Clin Res Ed) 284:1874–1875

    Article  CAS  Google Scholar 

  25. Krmar RT, Holtbäck U, Linné T et al (2011) Acute renal failure in dense deposit disease: Complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol 75:4–10

    PubMed  Google Scholar 

  26. Kurtz KA, Schlueter AJ (2002) Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher 17:135–137

    Article  PubMed  Google Scholar 

  27. McCaughan JA, O’Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant 12:1046–1051

    Article  CAS  PubMed  Google Scholar 

  28. Jokiranta TS, Solomon A, Pangburn MK et al (1999) Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 163(8):4590–4596

    CAS  PubMed  Google Scholar 

  29. Le Quintrec M, Lionet A, Kandel C et al (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65:484–489

    Article  CAS  PubMed  Google Scholar 

  30. Payette A, Patey N, Dragon-Durey MA et al (2015) A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 30:1033–1037

    Article  PubMed  Google Scholar 

  31. Rousset-Rouvière C, Cailliez M, Garaix F et al (2014) Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29:1107–1111

    Article  PubMed  Google Scholar 

  32. Gurkan S, Fyfe B, Weiss L et al (2013) Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28:1975–1981

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S (2013) C3 glomerulonephritis associated with monoclonal gammopathy: A case series. Am J Kidney Dis 62(3):506–514 (Sep)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik II für Nephrologie, Hypertensiologie und Intensivmedizin, St. Joseph Krankenhaus Berlin, Wüsthoffstraße 15, 12101, Berlin, Deutschland

    A. Gontcharov & C. Erley

Authors
  1. A. Gontcharov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Erley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gontcharov.

Ethics declarations

Interessenkonflikt

A. Gontcharov und C. Erley geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Es werden medizinische Medikamentenstudien zitiert.

Additional information

Redaktion

G. Wolf, Jena

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gontcharov, A., Erley, C. Adipöser Patient mit Luftnot und Stauungsdermatitis. Nephrologe 11, 428–436 (2016). https://doi.org/10.1007/s11560-016-0102-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-016-0102-1

Search

Navigation